Diamedizen 30 mg MR - 30 F.C. Tablet

Antidiabetic agent belongs to sulfonylurea group used in the treatment of type 2 diabetes mellitus.

Administer with meals (modified-release tablet should be administered with breakfast).

Hypoglycemia, hypertension, angina pectoris, peripheral edema, headache, dizziness, depression, insomnia, neuralgia, dermatological disorders, dermatitis, skin rash ( includes maculopapular rash, morbilliform rash), pruritus, hyperlipidemia, lipid metabolism disorder, diarrhea, constipation, gastroenteritis, abdominal pain, gastritis, nausea, urinary tract infection, viral infection, back pain, arthralgia, asthenia, arthropathy, myalgia, arthritis, tendinopathy, conjunctivitis, otitis media, bronchitis, rhinitis, pharyngitis, upper respiratory tract infection, cough, pneumonia, sinusitis, increased lactate dehydrogenase and increased serum creatinine.

-Should not be given to patients suffering from hypersensitivity to gliclazide. -Not used in the treatment of type 1 diabetes mellitus. -All sulfonylurea drugs are capable of producing severe hypoglycemia, so use with caution with the patients having any of these risk factors: Deficient caloric intake, after severe or prolonged exercise, ethanol consumption, using more than one glucose-lowering drug, elderly patients, malnourished patients, and in patients with impaired renal or hepatic function. -In case of diabetic patients who has undergone bariatric surgery: Use an antidiabetic agent without the potential for hypoglycemia if possible; hypoglycemia may occur after gastric bypass, sleeve gastrectomy. -In case of diabetic patients who has undergone bariatric surgery: Use immediate release formulations after surgery to minimize the potential effects of bypassing stomach and proximal small bowel with gastric bypass. -Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia. -Use with caution in hepatic impairment. -Use with caution in renal impairment. -In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Store at room temperature.

-Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of alcohol (ethyl). -Alpha-Lipoic Acid: May enhance the hypoglycemic effect of antidiabetic agents. -Amiodarone: May enhance the hypoglycemic effect of Sulfonylureas. -Antidiabetic agents: May enhance the hypoglycemic effect of hypoglycemia-associated agents. -Beta-blockers: May enhance the hypoglycemic effect of Sulfonylureas. -Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. -Chloramphenicol: May increase the serum concentration of Sulfonylureas. -Clarithromycin: May enhance the hypoglycemic effect of Sulfonylureas. -Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. -Direct acting antiviral agents (HCV): May enhance the hypoglycemic effect of antidiabetic agents. -Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. -Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Omeprazole: May increase the serum concentration of Gliclazide. -Quinolones: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Salicylates: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -St John's Wort: May decrease the serum concentration of Gliclazide. -Sulfonamide antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. -Tetracyclines: May enhance the hypoglycemic effect of Sulfonylureas. -Thiazide diuretics: May diminish the therapeutic effect of antidiabetic agents. -Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. -Vitamin K antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of vitamin K antagonists. -Voriconazole: May increase the serum concentration of Sulfonylureas.

-Gliclazide is contraindicated for use during pregnancy. Agents other than gliclazide are currently recommended to treat diabetes mellitus in pregnancy. -It is not known if gliclazide is present in breast milk. Use is contraindicated in breastfeeding mothers. -Ask your physician before taking any medication during pregnancy and lactation.

MEDIZEN PHARMACEUTICAL INDUSTRIES